All-cause mortality and hospitalization rates and inpatient expenditures among Medicare fee-for-service beneficiaries decreased from 1999 to 2013.
All-cause mortality and hospitalization rates and inpatient expenditures among Medicare fee-for-service beneficiaries decreased from 1999 to 2013, according to a study published in JAMA.
According to lead author Harlan M. Krumholz, MD, MS, professor of cardiology at the Yale School of Medicine and director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, the study’s findings suggest a “remarkable improvement in health and healthcare” in the United States. He attributed this improvement to changes in healthcare technology, delivery, and behaviors.
“The improvements that we observed were extraordinarily broad based,” he explained in an interview with JAMA. “We looked at various different subgroups: we looked by age, we looked by sex, we looked by race. And there was evidence of these improvements everywhere. There still remains some disparities between blacks and whites but both groups experienced this dramatic improvement.”
Dr Krumholz and colleagues examined a sample of 68,374,904 adults age 65 years or older and in Medicare fee-for-service or Medicare Advantage determined all-cause mortality among this population declined from 5.3% in 1999 to 4.5% in 2013. Inpatient expenditures declined from $3290 to $2801 per Medicare fee-for-service beneficiary.
Care for fee-for-service beneficiaries in the last 6 months of life also improved with hospitalizations down from 131 to 103 per 100 deaths and inpatient expenditures decreased from $17,423 in 2009 to $13,388 in 2013.
During the time studied, more patients were being discharged to rehabilitation and nursing facilities or with home healthcare and the proportion of patients discharged to home without care steadily declined.
“Even though it is difficult to disentangle the specific reasons for improvement, it is clear that over the past 15 years there have been marked reductions in mortality, hospitalization, and adverse hospital outcomes among the Medicare population aged 65 years or older,” the authors wrote.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More